3388-79-2

Basic information

• Product Name: 2-PIPERAZIN-2-YL-ETHANOL
• Synonyms: 2-PIPERAZIN-2-YL-ETHANOL-2HCl;2-(Piperazin-2-yl)ethanol dihydrochloride;2-piperazineethanol dihydrochloride;2-hydroxyethyl dihydrogenphosphate;Aethylenglykol-monophosphorsaeure;Ethylene glycol,monophosphated
• CAS NO: 3388-79-2
• Molecular Formula: C₆H₁₄N₂O
• Molecular Weight: 130.19
• Mol File: 3388-79-2.mol

Chemical Properties

• Boiling Point: 270.4±20.0 °C(Predicted)
• Appearance: /
• Density: 0.974±0.06 g/cm3(Predicted)
• PKA: 15.11±0.10(Predicted)
• CAS DataBase Reference: 2-PIPERAZIN-2-YL-ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERAZIN-2-YL-ETHANOL(3388-79-2)
• EPA Substance Registry System: 2-PIPERAZIN-2-YL-ETHANOL(3388-79-2)

Safety Data

• Hazardous Substances Data: 3388-79-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-PIPERAZIN-2-YL-ETHANOL is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of drugs with vasodilatory and cardiovascular effects, aiding in the treatment of different medical conditions.
Used in Chemical Synthesis:
As a derivative of piperazine, 2-PIPERAZIN-2-YL-ETHANOL is utilized as a building block in the creation of diverse organic compounds, expanding its applications across various chemical synthesis processes.
Used in Cosmetic and Personal Care Products:
2-PIPERAZIN-2-YL-ETHANOL is used as a solvent and additive in cosmetic formulations for its ability to dissolve various substances and enhance the performance of personal care products, while ensuring safety and efficacy in their applications.
Used in Research and Development:
In the scientific community, 2-PIPERAZIN-2-YL-ETHANOL is employed in research and development for studying its properties and potential applications, furthering the understanding of its role in chemical and medical fields.

Upstream product

• 33422-35-4 ethyl 2-(3-oxopiperazin-2-yl)acetate 
• 6705-31-3 2-(2-hydroxyethyl)-pyrazine 
• 89852-17-5 methyl 2-(3-oxopiperazin-2-yl)acetate 
• 109-08-0 2-Methylpyrazine 
• 1404504-29-5 4-chloro-3,5-diphenyl-1H-pyrazolo[3,4-c] pyridazine 
• 77279-24-4 tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate 

Downstream Products

• 100-02-7 4-nitro-phenol 
• 5167-08-8 1,4-diaza-bicyclo[3.2.1]octane 
• 1308375-21-4 3-((R)-2-amino-2-phenyl-ethyl)-1-(2,6-difluoro-benzyl)-5-[3-(2-hydroxy-ethyl)-piperazin-1-yl]-6-methyl-1H-pyrimidine-2,4-dione 

Relevant articles and documents

TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES

The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

Acetylcholine receptor ligands of formula I wherein D, E and G are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the sam

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS

The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed

N,N-diacylpiperazine tachykinin antagonists

Diacylpiperazines of general structure STR1 are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.

1,4-Diazabicyclo[3.2.1]octanes

The compounds 4-carbethoxy-1,4-diazabicyclo[3.2.1]octane and 4-diethylcarbamyl-1,4-diazabicyclo[3.2.1]octane, said compounds having utility as antifilarial agents.